ARB gets supplemental nod for pediatric hypertension

Novartis has received word from the FDA that a supplemental application for angiotensin II receptor blocker (ARB) valsartan (Diovan) has been approved that will permit the drug be used to treat pediatric hypertension in patients six to 16 years old. The tablets were previously approved for use in adults for the treatment of hypertension and heart failure, and to reduce cardiovascular mortality in post-myocardial infarction patients.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.